Canakinumab in patients with COVID-19 and type 2 diabetes - A multicentre, randomised, double-blind, placebo-controlled trial.
Hepprich M., Mudry J.M., Gregoriano C., Jornayvaz F.R., Carballo S., Wojtusciszyn A., Bart P.A., Chiche J.D., Fischli S., Baumgartner T. et al., 2022/11. EClinicalMedicine, 53 p. 101649. Peer-reviewed.
ici le détail